Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Third Quarter Financial Results
Date:11/5/2010

of LX1031 has progressed with the goal of achieving a lower and less frequent dosing regimen that will provide a similar safety and efficacy profile to that observed with the original formulation.  In addition, LX1033, a back-up compound that is approximately 10-fold more potent than LX1031, has completed IND-enabling studies.  It is anticipated that LX1033 will commence Phase 1 testing in the first quarter of 2011.
  • Rheumatoid Arthritis:  Lexicon completed dosing in the expanded Phase 2a clinical trial of its drug candidate for rheumatoid arthritis, LX2931, an inhibitor of sphingosine-1-phosphate lyase.  Top-line data from the study, which enrolled 208 patients and was conducted at multiple centers in the United States and Eastern Europe, are expected to be available by the end of the year.
  • Carcinoid Syndrome:  Enrollment in both the United States and Europe is continuing in the Phase 2a trials for LX1032, an inhibitor of tryptophan hydroxylase that reduces peripheral serotonin production without affecting brain serotonin levels. Preliminary data from both trials are expected to be available in the first half of 2011.

  • Financial Results and EventsOn July 30, 2010, Lexicon exercised a restructured purchase option under its drug development financing collaboration with Symphony Icon Holdings LLC and acquired all the equity of Symphony Icon, Inc., thereby reacquiring all rights to LX1031, LX1032, LX1033 and the other drug programs subject to the collaboration.  Pursuant to the amended terms of the purchase option, Lexicon paid Symphony Icon Holdings LLC $10 million and agr
    '/>"/>

    SOURCE Lexicon Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Lexicon to Present at Stifel Nicolaus Healthcare Conference
    2. Lexicon to Present at Morgan Stanley Global Healthcare Conference
    3. Lexicon to Present at Two Major Healthcare Investor Conferences
    4. Lexicon Announces Pricing of Common Stock in Public Offering
    5. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
    6. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
    7. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
    8. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
    9. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
    10. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
    11. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/15/2014)... SAN DIEGO , Dec. 15, 2014 /PRNewswire/ ... a three-dimensional biology company focused on delivering breakthrough ... by the industry and collaborators of its exVive3D ... was made widely available in full commercial release ... in the field, resulting in several awards for ...
    (Date:12/13/2014)... and Virgin Unite Canada, the non-profit foundation of the Virgin ... Canadian entrepreneurs tackling social and environmental challenges. Today, Sir ... Centre to announce the new partnership, which includes the development ... $1 million in seed capital provided by Virgin Unite Canada ... Foundation, founded by Alison Lawton . ...
    (Date:12/13/2014)... Charlotte, NC (PRWEB) December 13, 2014 ... nearly 3 million people between now and 2030." If ... will become the seventh most populous state in the ... Commerce is gathering at the Future of North Carolina ... We Ready? Do we have the necessary infrastructure in ...
    (Date:12/13/2014)... SAN ANTONIO , Dec. 12, 2014  Janssen ... of data at the San Antonio Breast Cancer Symposium ... alfa plus best supportive care (BSC) versus BSC when ... cancer receiving standard chemotherapy. This non-inferiority trial did not ... a 15 percent or greater increase in the risk ...
    Breaking Biology Technology:Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3North Carolina Chamber of Commerce: Asking Questions & Gathering Answers with a Futurist 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 4Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 5Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 6Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 7Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 8Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 9Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 10Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 11Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 12
    ... -- JERUSALEM and NEEDHAM, Massachusetts, August 18, 2010, ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in ...
    ... Fuels, Inc., a company focused on commercially producing low-carbon ... has produced cellulosic methanol from the initial phase of ... using non-food biomass. The first phase of ... thermo-chemical process, which uses heat, pressure, and steam to ...
    ... VANCOUVER, Canada, Aug. 17 Xenon Pharmaceuticals Inc. announced ... trial evaluating its novel topical XEN402 therapy for the ... developed by Xenon as a topical ointment formulation and ... 1 study in normal human volunteers.  The product was ...
    Cached Biology Technology:Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 2Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 3Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 4Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 5Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 6Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 7Range Fuels Produces Cellulosic Methanol From First Commercial Cellulosic Biofuels Plant 2Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402. 2
    (Date:12/10/2014)... , Dec. 8, 2014 You,ve been here before: ... but can,t remember your password, site key or the answer ... your first grade teacher? Today, Hoyos ... app that will finally put an end to the ... 1U TM . 1U leverages a user,s smartphone to ...
    (Date:12/10/2014)... Dec. 08, 2014 Research and Markets ... of the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration ... as rural banking and upgradation of the driver,s ... in the market. Besides the aforementioned projects, biometrics ...
    (Date:12/4/2014)... Fla. , Dec. 3, 2014  Crossmatch™, ... today announced that its DigitalPersona ® Pro ... readers have been deployed throughout First Bank branch ... South Carolina and Virginia. First ... Southern Pines, North Carolina , ...
    Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
    ... replanting of mangroves on the coasts of the Philippines could ... typhoons that hit the islands annually. This is one ... and massive mangrove replanting, that J.H. Primavera from the Southeast ... Salle University, both in the Philippines, cite in a paper ...
    ... technology used for building batteries for countless portable electronic ... economy is already upon us. In a ... International Journal of Nuclear Hydrogen Production and Applications , ... based in Bloomfield Hills, Michigan, explains that we already ...
    ... treatment of Alzheimer,s disease reports improvement in language ... accompanying the research, published today in the open ... within minutes of using this new treatment. ... published in BioMed Central,s Journal of Neuroinflammation, ...
    Cached Biology News:Mangroves key to saving lives 2Closing the hydrogen economic loop 2
    ... depletion cocktail is tailored to ... suspensions of rat spleen cells. ... StemSep (or compatible 0.5 Tesla) ... T cell content of the ...
    CleanCut agarose is used to prepare genomic DNA plugs for use in pulsed field gel electrophoresis (PFGE) applications. Supplied as a 12 ml solution of 2% agarose....
    ... an intelligent full microplate washer with a 96 ... instrument gives you the best of two worlds ... , Performance ,Separate wash and aspiration ... A dispense precision of better than 2% CV ...
    ... culture scale-up, these culture chambers produce cell ... 9 range and are useful alternatives ... • High mechanical • strength and structural ... shipping • Certified nonpyrogenic and sterilized by ...
    Biology Products: